【导读】多只牛股公告 兄弟姐妹们啊，今晚多只商业航天、脑机接口概念的牛股齐发公告，不是停牌核查就是提示风险！ 6天4板北斗星通：商业航天仅为公司产品和服务的应用场景之一 中国卫星（600118）公告，公司股票自2025年12月3日以来收盘价格累计上涨幅度为156.07%，同期申 万军工行业涨幅23.92%，上证A指涨幅5.31%，公司股票短期涨幅明显高于同期行业及上证指数涨幅， 但公司基本面未发生重大变化，存在市场情绪过热、非理性炒作风险，公司股票击鼓传花效应明显，交 易风险极大，存在股价短期快速回落风险。 北斗星通（002151）公告称，公司股票交易价格连续3个交易日收盘价格涨幅偏离值累计超过20%，属 于股票交易异常波动情形。公司留意到近期市场对于商业航天概念股的关注度颇高，公司主营业务为卫 星导航芯片、模组、天线、数据服务，下游应用场景包括测量测绘、智能驾驶、智慧农业、割草机器 人、无人机等，商业航天仅为公司产品和服务的应用场景之一，请投资者注意风险。 航天环宇：预计2025年公司商业航天相关收入占比不足15% 航天环宇公告，公司股票于2025年12月31日、2026年1月5日、1月6日连续三个交易日内 ...

Group 1 - The core viewpoint of the article highlights that International Medical (000516) has established a strong competitive edge and influence in the medical field through significant capital investments in the past [1] - Since the full opening of Xi'an International Medical Center Hospital, the company has experienced substantial growth in overall business scale, with a steady development trend and increasing brand influence and patient recognition [1] - From 2025 onwards, the company has faced a decrease in operating revenue year-on-year due to ongoing adjustments in industry policies, particularly the deepening of medical insurance payment reforms [1] Group 2 - The company will adhere to its strategic development goals, focusing on stable operations, enhancing medical quality and service experience, and building competitive advantages through differentiated strategies [1] - The company aims to actively adapt to industry changes and achieve continuous optimization of operational efficiency and improvement in business performance [1]

| 最高: 54.97 | 今年:4 | | --- | --- | | 最低:49.98 | 昨收:49 | | 量比: 0.70 | 换手:10 | | 委比:100.00% | 振幅:9. | | 每股收益:-0.49 | 股息(TTI | | 每股净资产:9.50 | 股息率(T | | 52周最高: 54.97 | 52周最低 | 【导读】多只牛股公告 中国基金报记者 泰勒 兄弟姐妹们啊，今晚多只商业航天、脑机接口概念的牛股齐发公告，不是停牌核查就是提示风险！ 6天4板北斗星通： 商业航天仅为公司产品和服务的应用场景之一 北斗星通公告称，公司股票交易价格连续3个交易日收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动情形。公司留意 到近期市场对于商业航天概念股的关注度颇高，公司主营业务为卫星导航芯片、模组、天线、数据服务，下游应用场景包括测量 测绘、智能驾驶、智慧农业、割草机器人、无人机等，商业航天仅为公司产品和服务的应用场景之一，请投资者注意风险。 | 成交量: 74.80万手 | | --- | | 成交额:39.95亿 | | 市盈率(TTM)： | | 市净率:5.79 | | 总市值: ...

Core Viewpoint - Baihua Pharmaceutical (600721) announced the termination of the planned change in control due to a lack of consensus with the counterparties, and the company's stock will resume trading on January 7, 2026 [1][2]. Group 1: Control Change Announcement - The controlling shareholders and actual controllers, Mi Naqi, Mi Enhua, and Yang Xiaoling, decided to terminate the control change due to disagreements on significant matters [1]. - The company had previously announced a potential share transfer that could lead to a change in control, prompting a temporary suspension of trading to ensure fair information disclosure and protect investor interests [1]. Group 2: Business Operations and Financial Performance - The company stated that the termination of the control change will not have a significant adverse impact on its operational performance and financial status [2]. - Baihua Pharmaceutical's main business includes early drug discovery, CMC development, clinical trials, registration applications, and various pharmaceutical services, providing comprehensive outsourcing and technology transfer services [2]. - For the first three quarters of 2025, the company reported revenue of 299 million yuan, a year-on-year increase of 2.74%, and a net profit of 32.67 million yuan, reflecting a year-on-year growth of 36.41% [3].

国家卫健委：以"强基、稳二、控三"为原则优化医疗机构功能定位和结构 近年来，中国医疗机构床位规模保持增势，每千人床位数已突破7张，远超欧美发达国家。与之相对应 的是公立医院住院率居高不下，上级医院虹吸病人而医疗"强基"缺少需求侧支撑。在此背景下，今年国 家卫健委将以"强基、稳二、控三"为原则，进一步调控三级医院规模和发展速度。 1月5日至6日，全国卫生健康工作会议在北京召开，会议在部署2026年工作时提出，今年全国卫生健康 系统要"倾力推进深化医改政策落实"，推进以公益性为导向的公立医院改革，与此同时，精准实施医疗 卫生强基和康复护理扩容提升工程。 "按照'强基、稳二、控三'原则优化医疗机构功能定位和结构，持续推进医疗卫生强基工程，稳定二级 医院运行并拓展康复护理功能，调控三级医院规模、发展速度，优化结构，全面提升医疗卫生服务公益 性、可及性和能力水平。"会议称。 根据国家卫健委去年12月发布的《2024年我国卫生健康事业发展统计公报》，2024年，公立医院床位扩 张态势有所减缓，但全国床位规模仍整体继续增加，每千人口医疗卫生机构床位数由2023年7.23张增加 到2024年7.32张。与此同时，当年，一二三 ...

（编辑 楚丽君） 证券日报网讯 1月6日，爱尔眼科在互动平台回答投资者提问时表示，"明眸远观福利"活动长期有效， 具体请参阅公司于2024年10月31日发布的《关于举办"上市十五年，回馈投资者"活动的公告》，可拨打 证券部电话0731-85136739，公司将协助联系落实。 ...

证券日报网讯 1月6日，三博脑科发布公告称，公司股票于2026年1月5日、1月6日，连续2个交易日内日 收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动的情形。经核实，公司前期披露的信息不存 在需要更正、补充之处；近期公共传媒未报道与公司相关且市场关注度较高的信息；近期公司经营情况 及内外部经营环境未发生重大变化。 （编辑 任世碧） ...

Core Viewpoint - Shantou City has been recognized for its healthcare capabilities with the inclusion of its General Medicine Department in the national clinical key specialty list, highlighting its leadership in medical services within the Chaoshan region [1] Group 1: Healthcare Development - The inclusion of Shantou City's General Medicine Department in the national clinical key specialty list signifies the city's growing influence as a provincial sub-center in healthcare services [1] - Shantou has established itself as a regional medical center, enhancing its position in the Shantou-Chaozhou-Jieyang urban agglomeration and providing advanced medical services to local residents [1][2] - The development of key specialties like oncology and general medicine strengthens the foundation of the provincial regional medical center, ensuring better healthcare access for the community [1] Group 2: Department Achievements - The General Medicine Department at Shantou City Central Hospital has a strong foundation, being one of the earliest and largest general medicine training bases in the region since its establishment in 2013 [2] - The department has developed an innovative "hospital-community-family" model for comprehensive healthcare management, facilitating seamless connections with community health service centers [2] - The department's focus on chronic disease management and preventive care has set a benchmark for improving grassroots healthcare services in the region [2] Group 3: Leadership and Research - The department is led by Wang Hao, a prominent figure in chronic disease research and a key talent in Guangdong's innovation plan, contributing significantly to national and provincial research projects [3] - Shantou City Central Hospital has achieved a breakthrough by having two national clinical key specialties, enhancing its reputation as a leading medical institution in the Chaoshan area [3] - The hospital aims to provide superior medical services to 15 million residents in Eastern Guangdong, aligning with the goals of provincial healthcare development [3]

格隆汇1月6日丨三博脑科(301293.SZ)公布股票交易异常波动公告，公司是以神经专科为特色的医疗服 务集团，下属院区主要为患者提供以高精尖神经外科为主的综合医疗服务。公司目前不涉及脑机接口产 品的研发、生产及销售，神经调控技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影 响，敬请注意投资风险。 ...

Core Insights - The "Bet on China" top ten core asset portfolio launched by the company has shown strong performance, with a 3.6% increase on January 5, 2026, outperforming the Shanghai Composite Index and Hang Seng Index [1] - The portfolio has continued to rise, with a 2.65% increase on January 6, 2026, further exceeding the performance of major indices [1] - Year-to-date, the portfolio has accumulated a 6.14% increase, significantly surpassing the Shanghai Composite Index's 2.89% and Hang Seng Index's 4.29% [1] Company Performance - Alibaba-W (HK09988) saw a total increase of 7.0% over two trading days [1] - China Ping An (SH601318) increased by 5.8% [1] - WuXi AppTec (HK02268) rose by 4.4% [1] - Tencent Holdings (HK00700) increased by 4.3% [1] - Trip.com Group-S (HK09961) rose by 4.1% [1] - Oriental Fortune (SZ300059) increased by 2.5% [1] - Zhongji Xuchuang (SZ300308) rose by 2.2% [1] - Luoyang Molybdenum (SH603993) increased by 2.2% [1] - Gold ETF (SH518880) rose by 2.1% [1] - Wanhua Chemical (SH600309) increased by 0.9% [1] Future Outlook - The strong performance of core assets is attributed to the company's deep insights into industry trends and the economic pulse of China [2] - The company aims to continue identifying quality assets in the context of China's economic transformation, providing investors with precise asset allocation references [2] - The recent performance is seen as just the beginning of the value release of the core assets [2]